Aurobindo Pharma's Apitoria to Acquire 80% Stake in A1 Biochem CRO for $17 Million, Building Integrated CRDMO Platform
核心洞察
Aurobindo Pharma subsidiary Apitoria will acquire an 80% stake in A1 Biochem Group (搜索) for USD 17 million, with the deal approved by Apitoria's board on July 23, 2026.
The acquisition brings front-end CRO capabilities including custom synthesis, medicinal chemistry, and analytical development, complementing Apitoria's existing large-scale API manufacturing.
A1 Biochem operates labs in Wilmington, North Carolina and Hyderabad, India, employs over 90 scientists, and has completed more than 800 projects for over 50 clients.
Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Apitoria Pharma Private Limited, has approved the acquisition of an 80% stake in the A1 Biochem Group (搜索) for USD 17 million. The decision was finalized at Apitoria's board meeting held on July 23, 2026, and disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The acquisition encompasses A1 Biochem Labs (India) Private Limited (搜索), the contract research organization (CRO) business of A1 Biochem Research (India) Private Limited (搜索), and A1 Biochem Labs LLC (搜索), USA. Upon completion, Apitoria will hold 80% ownership in A1 Biochem Labs (India) Private Limited, while the existing promoter of the A1 Biochem Group (搜索) will retain the remaining 20% stake. Additionally, A1 Biochem Labs (India) Private Limited will acquire 100% ownership of A1 Biochem Labs LLC, USA, and the CRO business of A1 Biochem Research (India) Private Limited will be transferred to A1 Biochem Labs (India) Private Limited.
Strategic Rationale: Building a CRDMO Platform
Aurobindo Pharma stated that the transaction aligns with its strategic objective of expanding its presence across the Active Pharmaceutical Ingredients (API) value chain. While Apitoria is currently engaged in large-scale, regulatory-compliant API manufacturing, the acquisition of front-end research and development capabilities will enable the company to establish a dedicated Contract Research, Development and Manufacturing Organization (CRDMO) platform.
The company noted that the acquisition will broaden its service offerings, facilitate longer customer engagement across the product life cycle, and complement its existing API manufacturing operations. By integrating A1 Biochem's established CRO platform with a client base of over 50 customers and more than 800 completed projects in the United States, Apitoria aims to create an integrated CRDMO platform that offers end-to-end solutions from early-stage research to commercial-scale production.
A1 Biochem Group (搜索): Capabilities and Financial Profile
A1 Biochem Group (搜索) is a Contract Research Organization providing chemistry services to pharmaceutical companies, biotechnology firms, and academic institutions. Its capabilities include custom synthesis, medicinal chemistry, route scouting, analytical development, and rapid process scale-up services. The group operates two scientific laboratories located in Wilmington, North Carolina, USA, and Hyderabad, India, employs more than 90 scientists, and has over 50 fume hoods.
The group is led by Dr. Rajendra Gadikota, who has more than 25 years of industry experience and will continue with the business after the acquisition. Besides serving customers in India and the United States, the group exports its services to the Netherlands, France, and Japan.
Financially, the A1 Biochem Group (搜索) reported turnover of ₹608.9 million in FY2023-24, ₹1,062.2 million in FY2024-25, and ₹1,024.42 million in FY2025-26. For FY2025-26, the group achieved an EBITDA of ₹465.46 million, reflecting substantial margins relative to its revenue base.
Transaction Structure and Timeline
The acquisition will be completed through cash consideration, with Apitoria investing USD 13.6 million to acquire its 80% ownership in the A1 Biochem Group (搜索), subject to customary adjustments at the closing of the transaction. Aurobindo Pharma clarified that the acquisition is not a related-party transaction, and neither the company's promoters nor promoter group entities have any interest in the target entities or business.
The transaction remains subject to the completion of conditions specified in the definitive agreements and customary regulatory approvals. It is expected to be completed within 90 to 120 days.
The regulatory filing was signed by B. Adi Reddy, Company Secretary, on behalf of Aurobindo Pharma Limited. A1 Biochem Labs (India) Private Limited (搜索) was incorporated on November 11, 2021, A1 Biochem Research (India) Private Limited (搜索) on July 18, 2022, and A1 Biochem Labs LLC (搜索), USA in September 2015.